SLC5A1 and type 1 diabetes mellitus: Many pyrazole and bipyrazole compounds in the preclinical studies of T1D exerted their antioxidant, anti-inflammatory, and hypoglycemic effects by lowering the blood glucose level or by regulating the peroxisome proliferator-activated receptor (PPARγ), sodium glucose co-transporter (SGLT1), and inhibiting some of the advanced glycation end product (RAGE) [43].